Treats relapsing forms of multiple sclerosis (MS). ANDA 214741, held by Scinopharm Taiwan. Glatiramer Acetate.
As of Nov 16, 2026, ANDA 214741 (Glatiramer Acetate), held by Scinopharm Taiwan, was first approved by FDA on Dec 31, 2025, with 0 approved supplements and 0 published complete response letters.
Glatiramer Acetate Injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 31, 2025 | Original application | Approved | None posted |
| Glatiramer Acetate20MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
| Glatiramer Acetate40MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters